论文部分内容阅读
目的比较盐酸米诺环素联合甲硝唑或替硝唑治疗慢性牙周炎的疗效及安全性。方法选取2014年2月—2016年2月于西安市第九医院进行治疗的慢性牙周炎患者260例作为研究对象,采用随机数字表法将其分为观察组与对照组各130例。对照组患者使用盐酸米诺环素联合甲硝唑治疗,观察组患者使用盐酸米诺环素联合替硝唑治疗,疗程均为4周。对比两组患者临床疗效、牙周各项指标以及不良反应。结果观察组治疗总有效率为94.62%,明显高于对照组的83.85%,差异有统计学意义(P<0.05)。治疗后,两组患者牙周各指标均较治疗前明显改善,其中观察组各指标均优于对照组,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率为8.46%,对照组为14.62%,两组差异不显著。观察组复发率为1.54%,对照组为6.92%,两组差异不显著。结论盐酸米诺环素联合替硝唑治疗慢性牙周炎疗效高于盐酸米诺环素联合甲硝唑治疗,安全性高,值得临床推广。
Objective To compare the efficacy and safety of minocycline plus metronidazole or tinidazole in the treatment of chronic periodontitis. Methods Two hundred and sixty patients with chronic periodontitis who were treated in the Ninth Hospital of Xi’an from February 2014 to February 2016 were selected as the research objects. Random number table was used to divide them into observation group and control group with 130 cases each. Patients in the control group were treated with minocycline plus metronidazole, and patients in the observation group were treated with minocycline plus tinidazole for 4 weeks. The clinical curative effect, periodontal indexes and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 94.62%, which was significantly higher than that of the control group (83.85%), the difference was statistically significant (P <0.05). After treatment, the indexes of periodontal in both groups were significantly improved compared with that before treatment, in which the indexes in the observation group were better than those in the control group, the difference was statistically significant (P <0.05). During the treatment, the incidence of adverse reactions in the observation group was 8.46% and in the control group was 14.62%, with no significant difference between the two groups. The recurrence rate was 1.54% in the observation group and 6.92% in the control group, with no significant difference between the two groups. Conclusion Minocycline hydrochloride combined with tinidazole in the treatment of chronic periodontitis is more effective than minocycline combined with metronidazole in treatment, which is safe and worthy of clinical promotion.